Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Company Overview

Anthera Pharmaceuticals, trading on the OTC Markets under the symbol ANTH, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for patients suffering from serious and rare inflammatory and autoimmune diseases. The company’s research and development efforts center on both biologic and small-molecule approaches designed to modulate key pathways in immune system dysfunction. Anthera’s strategy includes advancing lead candidates through late-stage clinical trials while exploring additional indications for its pipeline assets.

The company’s most advanced asset, blisibimod, is a selective antagonist of B-cell activating factor (BAFF) that has been evaluated in clinical studies for systemic lupus erythematosus (SLE) and primary immune thrombocytopenia (ITP). Anthera has also pursued early-stage programs in fibrotic conditions and cardiovascular diseases, leveraging its proprietary protein engineering platform to generate novel candidates with potential best-in-class attributes. Collaboration agreements with academic institutions and contract research organizations support Anthera’s efforts to accelerate development timelines and broaden the clinical assessment of its technologies.

Founded in the mid-2000s and headquartered in Hayward, California, Anthera has conducted multi-center trials across North America and Europe. The company’s management team comprises professionals with extensive experience in immunology, clinical operations and regulatory affairs, reflecting a commitment to rigorous clinical development and systematic advancement of its pipeline. Anthera’s operations include in-house research capabilities as well as strategic partnerships aimed at bridging the gap between laboratory discovery and commercial availability for patients in need.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 46 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/05/2018
• Today: 7/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ANTH
• CIK: 1316175
• Web: www.anthera.com
• Phone: (410) 350-1839
• Fax: 510-856-5597
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.23